arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Janux Therapeutics, Inc.

JANX Health Care Biotechnology: Pharmaceutical Preparations
$16.00
Today
as of Aug 5, 16:50 ET
Last 30 days +7.10% Jun 26 → Aug 05
$14.49 $15.10 $15.70 $16.31 $16.92 Jun 26 Jul 06 Jul 14 Jul 21 Jul 29 Aug 05
Open
$13.76
High
$13.82
Low
$13.16
Volume
$487,944
Avg Vol
$1M
Mkt Cap
$934M
P/E (TTM)
—
Beta
—
52w High
$35.34
52w Low
$12.12
Div Yield
—
Shares Out
$61M

Recent Press Releases & News last 60 days · 2 items

Jul 9 · 09:10 Simply Wall St.
Is Janux Therapeutics’ (JANX) Russell Index Exit Quietly Rewriting Its Investor Base and Story?
Jun 30 · 13:06 Insider Monkey
Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential?

Overview

52-week range
$12
$35
17% of range
Avg surprise (last 3)
+6.4%
Avg reaction (last 2)
+1.0%
50% positive
Latest IV / EM
89%
EM ±15.4% · $15 · Aug 21

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.55$-0.44$-0.33$-0.22$-0.11 Actual $-0.42Actual $-0.25Actual $-0.30Actual $-0.11Actual $-0.51Actual $-0.38Est $-0.43Actual $-0.55Est $-0.48Actual $-0.39Actual $-0.39Est $-0.50 JunSepMarJunSepMar/2025Jun/2025SepMar/2026
Revenue vs Net Income Revenue Net income
$-34M$-23M$-12M$-589,500$10M Jun 24Sep 24Mar 25Jun 25Sep 25Mar 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Thu May 7, 2026Mar/2026 $-0.39 $-0.50 +22.0% -2.6% -0.5% earnings
Tue Sep 30, 2025Sep 2025 $-0.39 — — — — financials
Thu Aug 7, 2025Jun/2025 $-0.55 $-0.48 -14.6% — — earnings
Thu May 8, 2025Mar/2025 $-0.38 $-0.43 +11.6% — +2.6% earnings
Mon Sep 30, 2024Sep 2024 $-0.51 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.11 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.30 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.25 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.42 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Thu Aug 6, 2026Jun/2026OTHER -$0.26-$0.55 +52.7%

Financials

Income statement (quarterly)

MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Revenue$4M—$10M$0$0—$439,000$9M
Cost of revenue————————
Gross profit————————
Operating income$-34M—$-35M$-45M$-35M—$-36M$-14M
Net income$-24M—$-24M$-34M$-24M—$-28M$-6M
EPS (diluted)$-0.39—$-0.39$-0.55$-0.38—$-0.51$-0.11

Balance sheet (quarterly)

MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Cash & equivalents$52M$52M$48M$52M$74M$431M$27M$15M
Inventory————————
Total current assets$1.00B$976M$998M$1.01B$1.02B$1.03B$666M$662M
Total assets$1.03B$1.00B$1.02B$1.03B$1.05B$1.06B$695M$691M
Long-term debt————————
Total liabilities$87M$45M$48M$42M$38M$39M$39M$34M
Total equity$942M$957M$977M$991M$1.01B$1.02B$656M$658M

Implied volatility — last 90 days

22%118%214%311%407% Jun 15 — IV 407% · EM ±29.5%Jun 17 — IV 85% · EM ±3.5%Jun 22 — IV 27% · EM ±5.6%Jun 23 — IV 60% · EM ±12.2%Jun 26 — IV 33% · EM ±6.4%Jun 30 — IV 41% · EM ±7.0%Jul 02 — IV 62% · EM ±10.0%Jul 03 — IV 64% · EM ±10.0%Jul 06 — IV 73% · EM ±10.1%Jul 07 — IV 77% · EM ±10.2%Jul 08 — IV 90% · EM ±11.3%Jul 09 — IV 97% · EM ±11.5%Jul 10 — IV 199% · EM ±22.0%Jul 13 — IV 48% · EM ±4.0%Jul 14 — IV 145% · EM ±10.5%Jul 15 — IV 280% · EM ±16.6%Jul 16 — IV 162% · EM ±6.8%Jul 20 — IV 26% · EM ±6.2%Jul 21 — IV 22% · EM ±5.2%Jul 22 — IV 55% · EM ±12.5%Jul 23 — IV 33% · EM ±7.3%Jul 24 — IV 51% · EM ±11.3%Jul 27 — IV 68% · EM ±14.1%Jul 28 — IV 52% · EM ±10.7%Jul 29 — IV 66% · EM ±13.2%Jul 30 — IV 103% · EM ±20.2%Jul 31 — IV 55% · EM ±10.5%Aug 03 — IV 87% · EM ±15.3%Aug 04 — IV 89% · EM ±15.4%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,164.75-0.4%
JNJ
Johnson & Johnson
$624.1B $258.23+0.2%
ABBV
AbbVie Inc.
$454.8B $246.35+0.1%
MRK
Merck & Company, Inc.
$321.6B $129.20+0.7%
PM
Philip Morris International Inc
$299.3B $188.93-0.0%
NVS
Novartis AG
$297.9B $154.440.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in